| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 49 | 2024 | 2567 | 3.000 |
Why?
|
| Osteosarcoma | 22 | 2024 | 909 | 2.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 55 | 2023 | 11868 | 1.430 |
Why?
|
| Neuroectodermal Tumors, Primitive | 10 | 2007 | 135 | 1.170 |
Why?
|
| Ifosfamide | 21 | 2023 | 233 | 1.080 |
Why?
|
| Etoposide | 16 | 2023 | 636 | 0.650 |
Why?
|
| Rhabdomyosarcoma | 10 | 2018 | 354 | 0.640 |
Why?
|
| Vincristine | 21 | 2023 | 1039 | 0.630 |
Why?
|
| Soft Tissue Neoplasms | 9 | 2009 | 1165 | 0.520 |
Why?
|
| Doxorubicin | 24 | 2023 | 2230 | 0.500 |
Why?
|
| Cyclophosphamide | 17 | 2021 | 2228 | 0.450 |
Why?
|
| Fibrosarcoma | 6 | 2002 | 313 | 0.450 |
Why?
|
| Cisplatin | 11 | 2019 | 1658 | 0.440 |
Why?
|
| Child | 113 | 2024 | 80564 | 0.400 |
Why?
|
| Dactinomycin | 13 | 2009 | 304 | 0.390 |
Why?
|
| Child, Preschool | 78 | 2021 | 42500 | 0.360 |
Why?
|
| Disease-Free Survival | 21 | 2017 | 6832 | 0.350 |
Why?
|
| Sarcoma | 11 | 2009 | 1802 | 0.350 |
Why?
|
| Translocation, Genetic | 7 | 2009 | 1394 | 0.330 |
Why?
|
| Adolescent | 89 | 2021 | 88835 | 0.320 |
Why?
|
| Infant | 63 | 2021 | 36386 | 0.300 |
Why?
|
| Fibromatosis, Aggressive | 3 | 2012 | 125 | 0.300 |
Why?
|
| Laryngeal Neoplasms | 2 | 2009 | 512 | 0.290 |
Why?
|
| Nose Neoplasms | 1 | 2009 | 249 | 0.280 |
Why?
|
| Topotecan | 4 | 2021 | 130 | 0.270 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 258 | 0.260 |
Why?
|
| Survival Rate | 22 | 2019 | 12795 | 0.260 |
Why?
|
| Neuroblastoma | 9 | 2003 | 1263 | 0.260 |
Why?
|
| Neoplasms, Second Primary | 3 | 2010 | 1050 | 0.250 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 1 | 2005 | 19 | 0.250 |
Why?
|
| Combined Modality Therapy | 21 | 2022 | 8529 | 0.240 |
Why?
|
| Hearing Loss | 2 | 2010 | 784 | 0.240 |
Why?
|
| Lymphocyte Count | 1 | 2007 | 790 | 0.240 |
Why?
|
| Methotrexate | 10 | 2019 | 1722 | 0.230 |
Why?
|
| Thoracic Neoplasms | 3 | 1994 | 267 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2022 | 9373 | 0.210 |
Why?
|
| Attitude to Death | 3 | 2007 | 399 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 5 | 2019 | 2895 | 0.200 |
Why?
|
| Testis | 6 | 2014 | 780 | 0.190 |
Why?
|
| Truth Disclosure | 5 | 2016 | 433 | 0.190 |
Why?
|
| Retroperitoneal Space | 1 | 2001 | 173 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2022 | 247 | 0.180 |
Why?
|
| Pelvic Bones | 2 | 2017 | 274 | 0.180 |
Why?
|
| Antineoplastic Agents | 12 | 2011 | 13648 | 0.180 |
Why?
|
| Neoplasms | 22 | 2016 | 22340 | 0.170 |
Why?
|
| Male | 99 | 2021 | 363698 | 0.170 |
Why?
|
| Humans | 147 | 2024 | 765968 | 0.170 |
Why?
|
| Mesna | 3 | 2005 | 62 | 0.170 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2020 | 101 | 0.170 |
Why?
|
| Neoplasm Metastasis | 9 | 2019 | 4893 | 0.170 |
Why?
|
| Drug Administration Schedule | 13 | 2012 | 4850 | 0.170 |
Why?
|
| Ribs | 2 | 2003 | 254 | 0.160 |
Why?
|
| Female | 93 | 2021 | 396112 | 0.160 |
Why?
|
| Prognosis | 25 | 2022 | 29922 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 1995 | 3646 | 0.150 |
Why?
|
| Carboplatin | 1 | 2001 | 789 | 0.150 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 3 | 1994 | 44 | 0.150 |
Why?
|
| Neuroectodermal Tumors | 1 | 1997 | 23 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2016 | 3537 | 0.140 |
Why?
|
| Cytarabine | 6 | 2009 | 698 | 0.140 |
Why?
|
| Treatment Outcome | 30 | 2016 | 65188 | 0.140 |
Why?
|
| Parents | 6 | 2011 | 3592 | 0.140 |
Why?
|
| Urogenital Neoplasms | 1 | 2018 | 129 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2017 | 183 | 0.130 |
Why?
|
| Palliative Care | 7 | 2008 | 3645 | 0.130 |
Why?
|
| Spermatogenesis | 4 | 2014 | 260 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2009 | 4044 | 0.130 |
Why?
|
| Forearm | 1 | 1998 | 427 | 0.130 |
Why?
|
| Lymph Node Excision | 2 | 2001 | 1259 | 0.120 |
Why?
|
| Adult | 56 | 2019 | 223044 | 0.120 |
Why?
|
| Receptors, Cell Surface | 3 | 2015 | 2817 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 15 | 3 | 2009 | 360 | 0.120 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 11206 | 0.120 |
Why?
|
| Follow-Up Studies | 18 | 2019 | 39193 | 0.120 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2015 | 40 | 0.120 |
Why?
|
| Communication | 6 | 2016 | 3916 | 0.120 |
Why?
|
| Bone Marrow | 4 | 2020 | 2921 | 0.110 |
Why?
|
| Smegmamorpha | 2 | 2003 | 14 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 639 | 0.110 |
Why?
|
| Rhabdomyoma | 1 | 2013 | 56 | 0.110 |
Why?
|
| Parotid Neoplasms | 2 | 2006 | 157 | 0.110 |
Why?
|
| Receptor, erbB-2 | 3 | 2014 | 2593 | 0.100 |
Why?
|
| Hedgehog Proteins | 2 | 2018 | 774 | 0.100 |
Why?
|
| Terminal Care | 6 | 2005 | 1774 | 0.100 |
Why?
|
| ras Proteins | 1 | 2018 | 1053 | 0.100 |
Why?
|
| Alkylating Agents | 1 | 1993 | 134 | 0.100 |
Why?
|
| Cardiotonic Agents | 1 | 2015 | 538 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2019 | 1776 | 0.100 |
Why?
|
| Barbiturates | 1 | 1992 | 113 | 0.100 |
Why?
|
| Muscle Neoplasms | 1 | 2013 | 130 | 0.100 |
Why?
|
| Ovary | 2 | 2009 | 956 | 0.100 |
Why?
|
| Extremities | 1 | 2017 | 869 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2015 | 6499 | 0.090 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 393 | 0.090 |
Why?
|
| Infant, Newborn | 18 | 2021 | 26346 | 0.090 |
Why?
|
| Celiac Plexus | 1 | 1990 | 34 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2005 | 633 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2013 | 2505 | 0.090 |
Why?
|
| Aftercare | 1 | 2016 | 911 | 0.090 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1990 | 38 | 0.080 |
Why?
|
| Morphine | 4 | 1996 | 660 | 0.080 |
Why?
|
| Professional-Family Relations | 3 | 2011 | 501 | 0.080 |
Why?
|
| Epiglottis | 1 | 2009 | 80 | 0.080 |
Why?
|
| Existentialism | 1 | 2009 | 38 | 0.080 |
Why?
|
| Antidotes | 1 | 2010 | 138 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2009 | 20659 | 0.080 |
Why?
|
| Mercaptoethanol | 1 | 1989 | 61 | 0.080 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2010 | 116 | 0.080 |
Why?
|
| Pain | 6 | 2005 | 5077 | 0.080 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2000 | 97 | 0.080 |
Why?
|
| Retrospective Studies | 23 | 2022 | 81514 | 0.080 |
Why?
|
| Survival Analysis | 7 | 2005 | 10070 | 0.080 |
Why?
|
| Medical Oncology | 3 | 2010 | 2339 | 0.080 |
Why?
|
| Prednisolone | 5 | 1992 | 324 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2009 | 350 | 0.080 |
Why?
|
| Leukemia, Myeloid | 2 | 2006 | 696 | 0.070 |
Why?
|
| Remission Induction | 8 | 2004 | 2411 | 0.070 |
Why?
|
| Academies and Institutes | 1 | 2010 | 326 | 0.070 |
Why?
|
| Glottis | 1 | 2009 | 212 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2016 | 1885 | 0.070 |
Why?
|
| Lipoma | 1 | 2010 | 294 | 0.070 |
Why?
|
| Liver Neoplasms | 7 | 1998 | 4353 | 0.070 |
Why?
|
| Parent-Child Relations | 3 | 2007 | 774 | 0.070 |
Why?
|
| Treatment Failure | 4 | 2017 | 2652 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 360 | 0.070 |
Why?
|
| Recurrence | 6 | 2008 | 8501 | 0.070 |
Why?
|
| Infusions, Intravenous | 3 | 2002 | 2229 | 0.070 |
Why?
|
| Cancer Care Facilities | 1 | 2010 | 426 | 0.070 |
Why?
|
| Hematuria | 1 | 1989 | 230 | 0.070 |
Why?
|
| Liposarcoma | 1 | 2010 | 288 | 0.070 |
Why?
|
| Lung Neoplasms | 5 | 2019 | 13451 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 2 | 2018 | 2921 | 0.070 |
Why?
|
| Hermaphroditic Organisms | 2 | 2003 | 7 | 0.070 |
Why?
|
| Axilla | 1 | 2009 | 615 | 0.070 |
Why?
|
| Hematology | 1 | 2010 | 243 | 0.070 |
Why?
|
| Spinal Neoplasms | 2 | 2009 | 708 | 0.070 |
Why?
|
| Monosomy | 1 | 1986 | 52 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 1998 | 430 | 0.070 |
Why?
|
| Wilms Tumor | 1 | 2009 | 379 | 0.070 |
Why?
|
| Menarche | 1 | 2009 | 532 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2019 | 5753 | 0.070 |
Why?
|
| Culture | 2 | 2009 | 622 | 0.070 |
Why?
|
| Puberty | 1 | 2009 | 491 | 0.070 |
Why?
|
| Sex Determination Processes | 2 | 2003 | 61 | 0.060 |
Why?
|
| Amifostine | 1 | 2006 | 39 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 682 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 255 | 0.060 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2010 | 302 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1986 | 311 | 0.060 |
Why?
|
| Cohort Studies | 7 | 2019 | 41649 | 0.060 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2006 | 91 | 0.060 |
Why?
|
| Disease Progression | 6 | 2019 | 13632 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 1998 | 2329 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 1997 | 412 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2016 | 2517 | 0.060 |
Why?
|
| Hospitals, Pediatric | 3 | 2010 | 1846 | 0.060 |
Why?
|
| Time Factors | 9 | 2019 | 40065 | 0.060 |
Why?
|
| Pyrroles | 1 | 2011 | 1119 | 0.060 |
Why?
|
| Physician-Patient Relations | 3 | 2007 | 3278 | 0.060 |
Why?
|
| Nerve Block | 2 | 1996 | 715 | 0.060 |
Why?
|
| Eye Neoplasms | 1 | 1986 | 304 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2017 | 8067 | 0.060 |
Why?
|
| Spirituality | 1 | 2009 | 430 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 12056 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 22 | 2 | 1997 | 348 | 0.060 |
Why?
|
| DNA, Neoplasm | 4 | 2013 | 1742 | 0.060 |
Why?
|
| Neural Tube Defects | 1 | 2006 | 256 | 0.060 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 950 | 0.060 |
Why?
|
| Protective Agents | 1 | 2005 | 151 | 0.060 |
Why?
|
| Retinoblastoma | 1 | 1986 | 316 | 0.060 |
Why?
|
| Camptothecin | 2 | 1998 | 600 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2017 | 6255 | 0.050 |
Why?
|
| Gene Amplification | 4 | 1993 | 1091 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2008 | 1153 | 0.050 |
Why?
|
| Boston | 7 | 2010 | 9338 | 0.050 |
Why?
|
| Neutropenia | 3 | 2011 | 893 | 0.050 |
Why?
|
| Cross-Cultural Comparison | 1 | 2007 | 634 | 0.050 |
Why?
|
| Infertility | 1 | 2010 | 654 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2016 | 3461 | 0.050 |
Why?
|
| Transplantation, Autologous | 3 | 2019 | 2120 | 0.050 |
Why?
|
| Cervical Vertebrae | 1 | 2009 | 974 | 0.050 |
Why?
|
| Indoles | 1 | 2011 | 1839 | 0.050 |
Why?
|
| Decision Making | 2 | 2011 | 3965 | 0.050 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2003 | 325 | 0.050 |
Why?
|
| Review Literature as Topic | 2 | 2015 | 297 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2018 | 1608 | 0.050 |
Why?
|
| Vinblastine | 2 | 2007 | 483 | 0.050 |
Why?
|
| Chromosome Aberrations | 4 | 1994 | 1774 | 0.050 |
Why?
|
| Genes, myc | 3 | 1993 | 393 | 0.050 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 266 | 0.050 |
Why?
|
| Biopsy | 3 | 2024 | 6763 | 0.050 |
Why?
|
| Prospective Studies | 9 | 2016 | 54802 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 1986 | 1385 | 0.050 |
Why?
|
| Giant Cell Tumors | 1 | 2002 | 89 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 3 | 1996 | 3401 | 0.050 |
Why?
|
| Receptors, Estrogen | 2 | 2008 | 2242 | 0.050 |
Why?
|
| Oncogenes | 3 | 2003 | 1235 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2017 | 3458 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2010 | 1135 | 0.050 |
Why?
|
| Hemangioblastoma | 1 | 2002 | 63 | 0.050 |
Why?
|
| Pulmonary Blastoma | 1 | 2001 | 43 | 0.050 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2003 | 243 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 1995 | 8041 | 0.050 |
Why?
|
| Uterine Rupture | 1 | 2001 | 67 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2010 | 2942 | 0.050 |
Why?
|
| Young Adult | 10 | 2019 | 59889 | 0.050 |
Why?
|
| Azacitidine | 2 | 1993 | 334 | 0.050 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2003 | 296 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2001 | 87 | 0.040 |
Why?
|
| Sacrum | 1 | 2022 | 270 | 0.040 |
Why?
|
| Whole-Body Irradiation | 1 | 2001 | 438 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 1999 | 1731 | 0.040 |
Why?
|
| Radiography | 2 | 2009 | 6919 | 0.040 |
Why?
|
| Daunorubicin | 3 | 1990 | 157 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2009 | 1873 | 0.040 |
Why?
|
| Survivors | 1 | 2010 | 2372 | 0.040 |
Why?
|
| Analgesia | 2 | 1995 | 461 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2010 | 2098 | 0.040 |
Why?
|
| Karyotyping | 5 | 1998 | 1178 | 0.040 |
Why?
|
| Luteinizing Hormone | 3 | 2014 | 826 | 0.040 |
Why?
|
| Mediastinal Neoplasms | 2 | 1993 | 403 | 0.040 |
Why?
|
| Artificial Gene Fusion | 1 | 1998 | 57 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 10383 | 0.040 |
Why?
|
| Nephroma, Mesoblastic | 1 | 1998 | 25 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2007 | 2020 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 710 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2009 | 4274 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 2660 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 2418 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2011 | 3584 | 0.040 |
Why?
|
| Stem Cells | 1 | 2011 | 3540 | 0.040 |
Why?
|
| Placenta Accreta | 1 | 2001 | 242 | 0.040 |
Why?
|
| Hepatoblastoma | 1 | 1998 | 90 | 0.040 |
Why?
|
| Infertility, Male | 1 | 2001 | 395 | 0.040 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1998 | 200 | 0.040 |
Why?
|
| Uterus | 1 | 2001 | 661 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2002 | 910 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2007 | 647 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2017 | 68 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 4108 | 0.040 |
Why?
|
| Paired Box Transcription Factors | 1 | 2018 | 204 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2011 | 5337 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 1028 | 0.030 |
Why?
|
| Muscle Cells | 1 | 2018 | 194 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 10729 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2020 | 2024 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 614 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2016 | 1560 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2010 | 2821 | 0.030 |
Why?
|
| Leukemia | 1 | 1985 | 1522 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 1993 | 730 | 0.030 |
Why?
|
| Pleural Neoplasms | 1 | 2001 | 581 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1986 | 1404 | 0.030 |
Why?
|
| Hydromorphone | 1 | 1996 | 70 | 0.030 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 1996 | 117 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1998 | 451 | 0.030 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2017 | 303 | 0.030 |
Why?
|
| Endodermal Sinus Tumor | 1 | 1996 | 52 | 0.030 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1999 | 335 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2003 | 2056 | 0.030 |
Why?
|
| Pediatrics | 1 | 2010 | 3606 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2016 | 233 | 0.030 |
Why?
|
| Thrombocytopenia | 2 | 2002 | 1171 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 2001 | 786 | 0.030 |
Why?
|
| Muscles | 2 | 2018 | 1578 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 3 | 1995 | 2729 | 0.030 |
Why?
|
| Periaqueductal Gray | 1 | 1995 | 111 | 0.030 |
Why?
|
| Pain, Intractable | 1 | 1996 | 132 | 0.030 |
Why?
|
| Critical Care | 1 | 2007 | 2712 | 0.030 |
Why?
|
| Consensus | 1 | 2024 | 3202 | 0.030 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 143 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 752 | 0.030 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2017 | 384 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2001 | 1181 | 0.030 |
Why?
|
| Mutation | 2 | 2018 | 30198 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 456 | 0.030 |
Why?
|
| Pneumonectomy | 2 | 2019 | 1128 | 0.030 |
Why?
|
| Mesencephalon | 1 | 1995 | 338 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 385 | 0.030 |
Why?
|
| Rhabdoid Tumor | 1 | 1995 | 209 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 591 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2009 | 36532 | 0.030 |
Why?
|
| Risk Factors | 5 | 2019 | 74840 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 5 | 2003 | 6113 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 1998 | 1009 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 1996 | 657 | 0.030 |
Why?
|
| Sulindac | 1 | 2012 | 29 | 0.030 |
Why?
|
| Isoxazoles | 1 | 1995 | 234 | 0.030 |
Why?
|
| Stress, Psychological | 3 | 2008 | 4533 | 0.030 |
Why?
|
| Family | 3 | 2016 | 3209 | 0.030 |
Why?
|
| Anesthesia, Conduction | 1 | 1996 | 264 | 0.030 |
Why?
|
| Quality of Health Care | 2 | 2005 | 4300 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 3423 | 0.030 |
Why?
|
| Hamartoma | 1 | 1994 | 233 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2001 | 2267 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2011 | 4025 | 0.020 |
Why?
|
| Analgesics, Opioid | 3 | 1996 | 3835 | 0.020 |
Why?
|
| Carcinoma | 1 | 2003 | 2312 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1998 | 1624 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 1701 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 1992 | 404 | 0.020 |
Why?
|
| Mesenchymoma | 1 | 1991 | 50 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 1991 | 127 | 0.020 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1992 | 258 | 0.020 |
Why?
|
| Analgesia, Epidural | 2 | 1996 | 337 | 0.020 |
Why?
|
| Genital Neoplasms, Male | 1 | 1990 | 68 | 0.020 |
Why?
|
| Ventilators, Mechanical | 1 | 1992 | 291 | 0.020 |
Why?
|
| Age Factors | 4 | 2015 | 18380 | 0.020 |
Why?
|
| Cell Separation | 1 | 1996 | 1718 | 0.020 |
Why?
|
| Risk | 3 | 2006 | 9591 | 0.020 |
Why?
|
| SEER Program | 1 | 2015 | 1446 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 1992 | 390 | 0.020 |
Why?
|
| Women's Health Services | 1 | 2010 | 87 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1991 | 587 | 0.020 |
Why?
|
| Iohexol | 1 | 1990 | 204 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 2007 | 1377 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1991 | 313 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2003 | 4913 | 0.020 |
Why?
|
| Femur | 1 | 2016 | 1310 | 0.020 |
Why?
|
| Life Tables | 1 | 1990 | 363 | 0.020 |
Why?
|
| Pregnancy | 3 | 2008 | 30260 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1994 | 704 | 0.020 |
Why?
|
| Physicians | 5 | 2007 | 4588 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2010 | 234 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 1994 | 1628 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 2056 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 898 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 1998 | 8611 | 0.020 |
Why?
|
| Hypnotics and Sedatives | 2 | 1995 | 1191 | 0.020 |
Why?
|
| Registries | 2 | 2002 | 8297 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2012 | 963 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 5783 | 0.020 |
Why?
|
| Astrocytoma | 1 | 1992 | 772 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 1993 | 914 | 0.020 |
Why?
|
| Testosterone | 2 | 2014 | 2494 | 0.020 |
Why?
|
| Reoperation | 1 | 1998 | 4294 | 0.020 |
Why?
|
| Menstruation | 1 | 2009 | 309 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 1998 | 2968 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 1994 | 1612 | 0.020 |
Why?
|
| Middle Aged | 8 | 2019 | 223009 | 0.020 |
Why?
|
| Brachytherapy | 1 | 1995 | 1222 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 12509 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1992 | 783 | 0.020 |
Why?
|
| RNA | 1 | 2017 | 2717 | 0.020 |
Why?
|
| Bupivacaine | 1 | 1990 | 432 | 0.020 |
Why?
|
| Genetic Markers | 2 | 1998 | 2601 | 0.020 |
Why?
|
| Bibliometrics | 1 | 2010 | 357 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2001 | 731 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 1986 | 351 | 0.020 |
Why?
|
| Data Collection | 2 | 2009 | 3318 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2009 | 1018 | 0.020 |
Why?
|
| Attitude | 1 | 2011 | 770 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2013 | 2666 | 0.020 |
Why?
|
| Resuscitation Orders | 1 | 2008 | 275 | 0.020 |
Why?
|
| Health Care Surveys | 2 | 2005 | 2424 | 0.020 |
Why?
|
| Research Personnel | 1 | 2010 | 590 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 1831 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 1253 | 0.020 |
Why?
|
| Computational Biology | 1 | 2017 | 3559 | 0.020 |
Why?
|
| Ultrasonography, Prenatal | 1 | 1993 | 1774 | 0.020 |
Why?
|
| Lung Diseases, Fungal | 1 | 1985 | 123 | 0.010 |
Why?
|
| Nervous System Neoplasms | 1 | 1985 | 91 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 2003 | 2548 | 0.010 |
Why?
|
| Amino Acid Sequence | 3 | 2003 | 13400 | 0.010 |
Why?
|
| Perception | 1 | 2011 | 1205 | 0.010 |
Why?
|
| Emotions | 1 | 2016 | 2763 | 0.010 |
Why?
|
| Ethanol | 1 | 1990 | 1323 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1994 | 1940 | 0.010 |
Why?
|
| Quality of Life | 4 | 2009 | 13462 | 0.010 |
Why?
|
| Chromosomes, Human, 19-20 | 1 | 2003 | 11 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 999 | 0.010 |
Why?
|
| Trust | 1 | 2009 | 533 | 0.010 |
Why?
|
| Chromosomes, Human, 13-15 | 1 | 2003 | 49 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1995 | 3715 | 0.010 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2003 | 9 | 0.010 |
Why?
|
| Sertoli Cells | 1 | 2003 | 51 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1987 | 1602 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 1990 | 1129 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1994 | 3690 | 0.010 |
Why?
|
| Transcription Factors | 2 | 2003 | 12131 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1999 | 15398 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 616 | 0.010 |
Why?
|
| Myeloablative Agonists | 1 | 2003 | 215 | 0.010 |
Why?
|
| Immunohistochemistry | 4 | 2003 | 11022 | 0.010 |
Why?
|
| United States | 4 | 2007 | 72903 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 2 | 2003 | 2631 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 251 | 0.010 |
Why?
|
| Japan | 1 | 2007 | 1415 | 0.010 |
Why?
|
| Pedigree | 1 | 2010 | 4526 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 2004 | 6203 | 0.010 |
Why?
|
| Palatal Neoplasms | 1 | 2002 | 37 | 0.010 |
Why?
|
| Bleomycin | 1 | 2003 | 491 | 0.010 |
Why?
|
| Faculty, Medical | 1 | 2010 | 1219 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 1884 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1998 | 9601 | 0.010 |
Why?
|
| Granulocytes | 1 | 1983 | 549 | 0.010 |
Why?
|
| Leucovorin | 1 | 2003 | 641 | 0.010 |
Why?
|
| Codon | 1 | 2003 | 595 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2003 | 939 | 0.010 |
Why?
|
| Models, Biological | 1 | 2017 | 9443 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1991 | 2844 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 9550 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1985 | 1617 | 0.010 |
Why?
|
| Gene Expression | 1 | 2013 | 7584 | 0.010 |
Why?
|
| Acute Disease | 2 | 2006 | 7232 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2017 | 7851 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2011 | 5881 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2018 | 11641 | 0.010 |
Why?
|
| Drug Resistance | 2 | 1996 | 1591 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2002 | 594 | 0.010 |
Why?
|
| Psychometrics | 1 | 2009 | 3062 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2000 | 124 | 0.010 |
Why?
|
| Anorexia | 1 | 2000 | 153 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1992 | 641 | 0.010 |
Why?
|
| Motivation | 1 | 2009 | 2018 | 0.010 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 1999 | 41 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2004 | 1326 | 0.010 |
Why?
|
| Receptor, trkC | 1 | 1998 | 63 | 0.010 |
Why?
|
| Maximum Allowable Concentration | 1 | 1998 | 64 | 0.010 |
Why?
|
| Epithelium | 1 | 2003 | 1599 | 0.010 |
Why?
|
| Terminally Ill | 1 | 2000 | 241 | 0.010 |
Why?
|
| Heart | 1 | 2011 | 4414 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24282 | 0.010 |
Why?
|
| Ploidies | 1 | 1998 | 287 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 1998 | 312 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2003 | 1144 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 1995 | 9071 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 2865 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 2391 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2009 | 26318 | 0.010 |
Why?
|
| Leukopenia | 2 | 1989 | 213 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 1996 | 134 | 0.010 |
Why?
|
| Cryptorchidism | 1 | 1977 | 152 | 0.010 |
Why?
|
| Hand | 1 | 2002 | 909 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1997 | 222 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 17594 | 0.010 |
Why?
|
| Subarachnoid Space | 1 | 1996 | 77 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 2 | 1997 | 6069 | 0.010 |
Why?
|
| DNA Probes | 1 | 1997 | 541 | 0.010 |
Why?
|
| Pain Measurement | 2 | 1996 | 3561 | 0.010 |
Why?
|
| Withholding Treatment | 1 | 2000 | 621 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1996 | 150 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 3946 | 0.010 |
Why?
|
| Constipation | 1 | 2000 | 568 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1995 | 395 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 23601 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2002 | 1375 | 0.010 |
Why?
|
| Germinoma | 1 | 1995 | 124 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1995 | 140 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1976 | 457 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 9249 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 18293 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 9649 | 0.010 |
Why?
|
| Home Care Services | 1 | 2000 | 660 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 22223 | 0.010 |
Why?
|
| Diarrhea | 1 | 2000 | 1316 | 0.010 |
Why?
|
| Injections | 1 | 1996 | 840 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2003 | 5379 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2007 | 3925 | 0.010 |
Why?
|
| Fatigue | 1 | 2000 | 1549 | 0.010 |
Why?
|
| Animals | 5 | 2013 | 168764 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 6493 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 6547 | 0.010 |
Why?
|
| Dyspnea | 1 | 2000 | 1352 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1993 | 363 | 0.010 |
Why?
|
| Aged | 3 | 2016 | 171117 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1995 | 1029 | 0.010 |
Why?
|
| Osteoma | 1 | 1991 | 12 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 3430 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2000 | 6322 | 0.010 |
Why?
|
| Thoracotomy | 1 | 1993 | 369 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1990 | 366 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 3596 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1990 | 226 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1996 | 2108 | 0.010 |
Why?
|
| Estradiol | 1 | 1977 | 1947 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1996 | 712 | 0.010 |
Why?
|
| Urinary Tract | 1 | 1993 | 305 | 0.010 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1991 | 168 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2003 | 21056 | 0.010 |
Why?
|
| Trisomy | 1 | 1991 | 259 | 0.010 |
Why?
|
| Teniposide | 1 | 1989 | 11 | 0.010 |
Why?
|
| Keratins | 1 | 1991 | 498 | 0.010 |
Why?
|
| Amsacrine | 1 | 1989 | 19 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1991 | 15747 | 0.000 |
Why?
|
| Orchiectomy | 1 | 1990 | 460 | 0.000 |
Why?
|
| Factor VIII | 1 | 1991 | 347 | 0.000 |
Why?
|
| Blast Crisis | 1 | 1989 | 102 | 0.000 |
Why?
|
| Macrophages | 1 | 1983 | 5772 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 18071 | 0.000 |
Why?
|
| Incidence | 1 | 2006 | 21480 | 0.000 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1992 | 480 | 0.000 |
Why?
|
| Thioguanine | 1 | 1987 | 45 | 0.000 |
Why?
|
| Hematopoiesis | 1 | 1996 | 2058 | 0.000 |
Why?
|
| Mice | 1 | 2013 | 81819 | 0.000 |
Why?
|
| Stomatitis | 1 | 1989 | 270 | 0.000 |
Why?
|
| Penicillium | 1 | 1985 | 23 | 0.000 |
Why?
|
| Mouth Mucosa | 1 | 1989 | 432 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1993 | 1494 | 0.000 |
Why?
|
| Feasibility Studies | 1 | 1997 | 5302 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1995 | 6309 | 0.000 |
Why?
|
| Logistic Models | 1 | 2000 | 13266 | 0.000 |
Why?
|
| Body Weight | 1 | 1996 | 4622 | 0.000 |
Why?
|
| Brain | 1 | 1992 | 27171 | 0.000 |
Why?
|
| Syndrome | 1 | 1991 | 3271 | 0.000 |
Why?
|
| Liver | 2 | 1991 | 7562 | 0.000 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1989 | 689 | 0.000 |
Why?
|
| Transcriptional Activation | 1 | 1990 | 1744 | 0.000 |
Why?
|
| Aspergillosis | 1 | 1985 | 242 | 0.000 |
Why?
|
| Metaphase | 1 | 1983 | 144 | 0.000 |
Why?
|
| Diploidy | 1 | 1983 | 141 | 0.000 |
Why?
|
| Candidiasis | 1 | 1985 | 371 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 12403 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1996 | 12437 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 5849 | 0.000 |
Why?
|
| Proteins | 1 | 1976 | 5995 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 14652 | 0.000 |
Why?
|
| DNA | 1 | 1994 | 7202 | 0.000 |
Why?
|
| Kidney | 1 | 1995 | 7066 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1993 | 7599 | 0.000 |
Why?
|
| Leydig Cells | 1 | 1977 | 55 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 1995 | 5444 | 0.000 |
Why?
|
| Inflammation | 1 | 1996 | 10850 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1976 | 1140 | 0.000 |
Why?
|
| Cytosol | 1 | 1977 | 885 | 0.000 |
Why?
|
| Organ Size | 1 | 1977 | 2260 | 0.000 |
Why?
|
| Rats | 2 | 1977 | 23707 | 0.000 |
Why?
|
| Kinetics | 1 | 1976 | 6274 | 0.000 |
Why?
|